GP Vivas · cardiovascular-health
Heart failure — structured viva
Structured oral on heart failure: the four pillars with trial numbers, rapid titration per STRONG-HF, device criteria, the HFpEF SGLT2i breakthrough, iron deficiency and palliative overlap.
On this page
Study tools
Target exams
RACGP CCEFRACGP oralsMRCGP SCA
Prompt
The examiner opens: 'A new HFrEF diagnosis walks into your surgery — walk me through the first month.' The viva branches through initiation, titration pace, devices, HFpEF and the palliative overlap.
Stem
You are the GP. A newly diagnosed 62-year-old man with LVEF 30% sits before you. Walk me through month one. [1]
References5ShowHide
- [1]McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF) N Engl J Med, 2014.PMID 25176015
- [2]McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF) N Engl J Med, 2019.PMID 31535829
- [3]Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF) Lancet, 2022.PMID 36356631
- [4]Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved) N Engl J Med, 2021.PMID 34449189
- [5]Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT) N Engl J Med, 2005.PMID 15659722